| UHC Medicaid Medical & Drug | Luxturna® (Voretigene Neparvovec-Rzyl) – Community Plan Medical Benefit Drug Policy | 2026-04-01 |
| UHC Medicaid Medical & Drug | Medical Therapies for Enzyme Deficiencies – Community Plan Medical Benefit Drug Policy | 2026-04-01 |
| UHC Medicaid Medical & Drug | Minimally Invasive Procedures for the Treatment of Upper Gastrointestinal Diseases – Community Plan Medical Policy | 2026-04-01 |
| UHC Medicaid Medical & Drug | Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease – Community Plan Medical Benefit Drug Policy | 2026-04-01 |
| UHC Medicaid Medical & Drug | Natalizumab (Tyruko® & Tysabri®) – Community Plan Medical Benefit Drug Policy | 2026-04-01 |
| UHC Medicaid Medical & Drug | Neurophysiologic Testing and Monitoring – Community Plan Medical Policy | 2026-04-01 |
| UHC Medicaid Medical & Drug | Niktimvo™ (Axatilimab-Csfr) – Community Plan Medical Benefit Drug Policy | 2026-04-01 |
| UHC Medicaid Medical & Drug | Nplate® (Romiplostim) – Community Plan Medical Benefit Drug Policy | 2026-04-01 |
| UHC Medicaid Medical & Drug | Ocrevus® (Ocrelizumab) and Ocrevus Zunovo® (Ocrelizumab and Hyaluronidase-Ocsq) – Community Plan Medical Benefit Drug Policy | 2026-04-01 |
| UHC Medicaid Medical & Drug | Off-Label/Unproven Specialty Drug Treatment – Community Plan Medical Benefit Drug Policy | 2026-04-01 |